Market Trends of Asia Pacific Wound Care Biologics Industry
The Diabetic Foot Ulcers Segment Is Expected to Hold a Significant Market Share During the Forecast Period
Diabetic foot ulcers (DFUs) are a significant and often debilitating complication of diabetes, affecting millions of individuals in Asia. As the prevalence of diabetes continues to rise, so does the burden of DFUs, creating an urgent need for effective treatments within the wound care biologics market.
Diabetic foot ulcers are chronic, non-healing wounds that typically develop on the feet or lower extremities of individuals with diabetes. These ulcers are caused by a combination of factors, including poor circulation, nerve damage (neuropathy), and impaired immune function, leading to delayed healing and an increased risk of infection. DFUs are a major cause of hospitalization, amputation, and reduced quality of life among diabetic patients.
The expanding market for wound care biologics targeting diabetic foot ulcers (DFUs) is intricately connected to the increasing prevalence of diabetes. For instance, a publication in the Journal of Diabetology in November 2023 highlighted that according to the International Diabetes Federation Atlas, a staggering 537 million adults globally had diabetes, with Asia alone contributing to 60% of this population. Projections suggest a 68% increase in diabetes prevalence in Southeast Asia by 2045.
A study published by the American Medical Association in November 2023 revealed that one-third of individuals with diabetes developed foot ulcers at some point in their lives. With the diabetes epidemic intensifying, there is a corresponding anticipation of heightened demand for effective treatments for DFUs.
Biologics, which are medical products derived from living organisms, have emerged as a promising avenue for treating DFUs. These innovative therapies aim to promote wound healing by addressing the underlying cellular and molecular mechanisms involved in the healing process. For instance, in May 2023, Stempeutics Research reported progress in their Phase 3 clinical trial for Stempeucel-DFU, an allogeneic mesenchymal stromal cell product candidate. The trial, which completed enrollment, evaluates the efficacy of a single peri-ulcer injection administered through various routes based on the location of the ulcer. The Drugs Controller General of India (DCGI) approved this Phase 3 trial, highlighting the significant potential of biologics in the treatment of DFUs.
As the prevalence of diabetes continues to rise, the burden of diabetic foot ulcers is expected to increase correspondingly, hence boosting segmental growth over the forecast period.
India is Expected to Hold a Significant Market Share Over the Forecast Period
India, with its burgeoning population and increasing incidences of accidents and burns, plays a pivotal role in shaping the wound biologics care market in Asia. As the country grapples with the challenges of managing wounds effectively, there is a growing recognition of the importance of innovative biological solutions.
India's significant share of the market is underpinned by the alarming prevalence of burn cases and road accidents. According to an article published by Cureus Inc. in February 2024, the country witnesses an estimated 6-7 million burn cases annually. Factors contributing to this high incidence included socioeconomic issues such as illiteracy, poverty, and limited awareness of safety measures. The problem was compounded by inadequate systematic burn care at basic and secondary healthcare levels, exacerbating the burden on healthcare infrastructure.
The Ministry of Road Transport and Highways' Road Accidents in India report highlights the country's escalating number of road accidents. In 2022 alone, 461 thousand road accidents were reported, marking an 11.9% increase compared to the previous year. These accidents not only result in physical injuries but also often lead to severe wounds requiring advanced medical intervention.
Amidst these challenges, there are promising developments in the field of wound management in India. An article published by Global Surgery Research in September 2023 reported a significant milestone, with the India Hub training over 500 practitioners in wound management. This underscored a concerted effort to enhance expertise and capabilities in addressing the complex needs of wound care across the country.
The wound biologics care market in India is likely to witness significant growth with the increasing burden of burn cases and road accidents, raising the requirement for wound biologics care over the forecast period.
